{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:23:11Z","timestamp":1773282191292,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The rapid emergence of SARS-CoV-2 prompted accelerated vaccine development, with neutralization assays serving as essential tools to evaluate vaccine-induced immune responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A <jats:italic>post-hoc<\/jats:italic> analysis of a Phase I\/II trial evaluated the immunogenicity of a bivalent SARS-CoV-2 protein vaccine. We assessed vaccine immunogenicity using live virus neutralization assays (LVNA) and pseudotyped virus neutralization assays (PVNA) to measure antibody responses against different variants, including Alpha B.1.1.7, Beta B.1.351, and Delta B.1.617.2. Various statistical techniques, including correlation coefficients, regression models, and Bland\u2013Altman plots, were employed to assess the relationship between antibody titers from the two assays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We analyzed 324 samples for Alpha and Beta variants and 505 for Delta. Compared with LVNA, the sensitivity and specificity of PVNA were over 90% across all variants, with accuracy rates of 98.8% for Alpha, 99.1% for Beta, and 94.3% for Delta. The Pearson correlation between PVNA and LVNA was strong for Alpha (CORR = 0.9614), Beta (CORR = 0.9517), and Delta (CORR = 0.9072). Bland-Altman plots and Kernel density plots indicated good agreement between PVNA and LVNA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our findings demonstrate a strong correlation between PVNA and LVNA results, supporting PVNA as a safe, scalable, and reliable surrogate for LVNA in evaluating vaccine immunogenicity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1650083","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:35:51Z","timestamp":1758638151000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative analysis of neutralization assays performed using live SARS-CoV-2 virus and pseudovirus to assess immunogenicity of a bivalent SARS-CoV-2 protein vaccine in humans"],"prefix":"10.3389","volume":"16","author":[{"given":"Cuige","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Baidoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/v14071560","article-title":"Overview of neutralization assays and international standard for detecting SARS-coV-2 neutralizing antibody","volume":"14","author":"Liu","year":"2022","journal-title":"Viruses"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065352","article-title":"Importance, applications and features of assays measuring SARS-coV-2 neutralizing antibodies","volume":"24","author":"Gattinger","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/vaccines9121376","article-title":"Overview of neutralizing antibodies and their potential in COVID-19","volume":"9","author":"Morales-N\u00fa\u00f1ez","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12050554","article-title":"SARS-coV-2 neutralization assays used in clinical trials: A narrative review","volume":"12","author":"Sun","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/oxfimm\/iqab005","article-title":"The role of pseudotype neutralization assays in understanding SARS CoV-2","volume":"2","author":"Cantoni","year":"2021","journal-title":"Oxf Open Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.981693","article-title":"Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay","volume":"13","author":"D\u2019Apice","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/v13040713","article-title":"Comparison of serological assays for the detection of SARS-coV-2 antibodies","volume":"13","author":"James","year":"2021","journal-title":"Viruses"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-021-00536-y","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays","volume":"16","author":"Bewley","year":"2021","journal-title":"Nat Protoc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/v12091011","article-title":"Characterisation of SARS-coV-2 lentiviral pseudotypes and correlation between pseudotype-based neutralisation assays and live virus-based micro neutralisation assays","volume":"12","author":"Hyseni","year":"2020","journal-title":"Viruses"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1184362","article-title":"Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature","volume":"14","author":"Cantoni","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab563","article-title":"Effects of severe acute respiratory syndrome coronavirus 2 strain variation on virus neutralization titers: therapeutic use of convalescent plasma","volume":"225","author":"Nguyen","year":"2022","journal-title":"J Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e615","DOI":"10.1002\/mco2.615","article-title":"Optimization and validation of a virus-like particle pseudotyped virus neutralization assay for SARS-CoV-2","volume":"5","author":"Liu","year":"2024","journal-title":"MedComm (2020)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.chom.2023.11.012","article-title":"Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster","volume":"32","author":"Wang","year":"2024","journal-title":"Cell Host Microbe"},{"key":"B17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jinf.2022.11.008","article-title":"Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial","volume":"86","author":"Wang","year":"2023","journal-title":"J Infect"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2456231","article-title":"Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants","volume":"24","author":"Wang","year":"2025","journal-title":"Expert Rev Vaccines"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0394-5","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay","volume":"15","author":"Nie","year":"2020","journal-title":"Nat Protoc"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/096228029900800204","article-title":"Measuring agreement in method comparison studies","volume":"8","author":"Bland","year":"1999","journal-title":"Stat Methods Med Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2009.05288.x","article-title":"Confidence in Altman-Bland plots: a critical review of the method of differences","volume":"37","author":"Ludbrook","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B22","volume-title":"Biosafety in Microbiological and Biomedical Laboratories","year":"2020"},{"key":"B23","volume-title":"Laboratory biosafety guidance related to SARS-CoV-2 (COVID-19): Interim guidance, 11 March 2024","year":"2024"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bsheal.2020.08.004","article-title":"Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro","volume":"2","author":"Yang","year":"2020","journal-title":"Biosafety Health"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.09.007","article-title":"Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial","volume":"32","author":"Krajden","year":"2014","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00161","article-title":"Pseudotype-based neutralization assays for influenza: a systematic analysis","volume":"6","author":"Carnell","year":"2015","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2022.126993","article-title":"Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies","volume":"258","author":"Xiang","year":"2022","journal-title":"Microbiol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11060994","article-title":"Evaluation of a pseudovirus neutralization assay for SARS-coV-2 and correlation with live virus-based micro neutralization assay","volume":"11","author":"Tolah","year":"2021","journal-title":"Diagn (Basel)"},{"key":"B30","volume-title":"Emergency Use Authorization for Vaccines to Prevent COVID-19: Guidance for Industry","year":"2022"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0272298","DOI":"10.1371\/journal.pone.0272298","article-title":"Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay","volume":"17","author":"Frische","year":"2022","journal-title":"PloS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1650083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:35:52Z","timestamp":1758638152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1650083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2025.1650083"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1650083","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"article-number":"1650083"}}